1
|
MacLean ELH, Yapa HM. Thinking beyond diagnostic accuracy to evaluate tuberculosis screening tests. Lancet Glob Health 2024; 12:e717-e718. [PMID: 38583457 DOI: 10.1016/s2214-109x(24)00061-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Accepted: 02/02/2024] [Indexed: 04/09/2024]
Affiliation(s)
- Emily L-H MacLean
- NHMRC Clinical Trial Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Sydney Infectious Diseases Institute, University of Sydney, Sydney, NSW, Australia.
| | - H Manisha Yapa
- Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Sydney Infectious Diseases Institute, University of Sydney, Sydney, NSW, Australia
| |
Collapse
|
2
|
De Vos E, Westreich D, Scott L, Voss de Lima Y, Stevens W, Hayes C, da Silva P, Van Rie A. Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality. PLOS GLOBAL PUBLIC HEALTH 2023; 3:e0001989. [PMID: 37656670 PMCID: PMC10473529 DOI: 10.1371/journal.pgph.0001989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Accepted: 07/07/2023] [Indexed: 09/03/2023]
Abstract
Studies assessing patient-centred outcomes of novel rifampicin resistant tuberculosis (RR-TB) diagnostics are rare and mostly apply conventional methods which may not adequately address biases. Even though the Xpert MTB/RIF molecular assay was endorsed a decade ago for simultaneous diagnosis of tuberculosis and RR-TB, the impact of the assay on mortality among people with RR-TB has not yet been assessed. We analysed data of an observational prospective cohort study (EXIT-RIF) performed in South Africa. We applied a causal inference approach using inverse odds of sampling weights to rectify survivor bias and selection bias caused by differing screening guidelines. We also adjusted for confounding using a marginal structural model with inverse probability of treatment weights. We estimated the total effect of an RR-TB diagnosis made by the Xpert assay versus the pre-Xpert diagnostic algorithm (entailing a targeted Line Probe Assay (LPA) among TB-confirmed patients) on two-year mortality and we assessed mediation by RR-treatment initiation. Of the 749 patients diagnosed with RR-TB [247 (33%) by the pre-Xpert diagnostic algorithm and 502 (67%) by the Xpert assay], 42.7% died. Of these, 364 (48.6%) patients died in the pre-Xpert group and 200 (39.8%) in the Xpert group. People diagnosed with RR-TB by the Xpert assay had a higher odds of RR-TB treatment initiation compared to those diagnosed by the targeted LPA-based diagnostic process (OR 2.79; 95%CI 2.19-3.56). Receiving an RR-TB diagnosis by Xpert resulted in a 28% reduction in the odds of mortality within 2 years after presentation to the clinic (ORCI 0.72; 95%CI 0.53-0.99). Causal mediation analysis suggests that the higher rate of RR-TB treatment initiation in people diagnosed by the Xpert assay explains the effect of Xpert on 2-year mortality [natural indirect effect odds ratio 0.90 (95%CI 0.85-0.96). By using causal inference methods in combination with high quality observational data, we could demonstrate that the introduction of the Xpert assay caused a 28% reduction in 2-year odds of mortality of RR-TB. This finding highlights the need for advocacy for a worldwide roll-out of rapid molecular tests. Because the effect is mainly caused by increased RR-TB treatment initiation, health care systems should also ensure timely initiation of effective treatment upon an RR-TB diagnosis.
Collapse
Affiliation(s)
| | - Daniel Westreich
- University of North Carolina, Chapel Hill, NC, United States of America
| | - Lesley Scott
- University of the Witwatersrand, Johannesburg, South Africa
| | | | - Wendy Stevens
- University of the Witwatersrand, Johannesburg, South Africa
- National Health Laboratory Service, Johannesburg, South Africa
| | - Cindy Hayes
- National Health Laboratory Services, Port Elizabeth, South Africa
| | - Pedro da Silva
- National Health Laboratory Service, Johannesburg, South Africa
| | | |
Collapse
|
3
|
Lee JH, Garg T, Lee J, McGrath S, Rosman L, Schumacher SG, Benedetti A, Qin ZZ, Gore G, Pai M, Sohn H. Impact of molecular diagnostic tests on diagnostic and treatment delays in tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2022; 22:940. [PMID: 36517736 PMCID: PMC9748908 DOI: 10.1186/s12879-022-07855-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Accepted: 11/08/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Countries with high TB burden have expanded access to molecular diagnostic tests. However, their impact on reducing delays in TB diagnosis and treatment has not been assessed. Our primary aim was to summarize the quantitative evidence on the impact of nucleic acid amplification tests (NAAT) on diagnostic and treatment delays compared to that of the standard of care for drug-sensitive and drug-resistant tuberculosis (DS-TB and DR-TB). METHODS We searched MEDLINE, EMBASE, Web of Science, and the Global Health databases (from their inception to October 12, 2020) and extracted time delay data for each test. We then analysed the diagnostic and treatment initiation delay separately for DS-TB and DR-TB by comparing smear vs Xpert for DS-TB and culture drug sensitivity testing (DST) vs line probe assay (LPA) for DR-TB. We conducted random effects meta-analyses of differences of the medians to quantify the difference in diagnostic and treatment initiation delay, and we investigated heterogeneity in effect estimates based on the period the test was used in, empiric treatment rate, HIV prevalence, healthcare level, and study design. We also evaluated methodological differences in assessing time delays. RESULTS A total of 45 studies were included in this review (DS = 26; DR = 20). We found considerable heterogeneity in the definition and reporting of time delays across the studies. For DS-TB, the use of Xpert reduced diagnostic delay by 1.79 days (95% CI - 0.27 to 3.85) and treatment initiation delay by 2.55 days (95% CI 0.54-4.56) in comparison to sputum microscopy. For DR-TB, use of LPAs reduced diagnostic delay by 40.09 days (95% CI 26.82-53.37) and treatment initiation delay by 45.32 days (95% CI 30.27-60.37) in comparison to any culture DST methods. CONCLUSIONS Our findings indicate that the use of World Health Organization recommended diagnostics for TB reduced delays in diagnosing and initiating TB treatment. Future studies evaluating performance and impact of diagnostics should consider reporting time delay estimates based on the standardized reporting framework.
Collapse
Affiliation(s)
- Jae Hyoung Lee
- grid.21107.350000 0001 2171 9311Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, USA
| | - Tushar Garg
- grid.21107.350000 0001 2171 9311Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
| | - Jungsil Lee
- grid.8991.90000 0004 0425 469XLondon School of Hygiene & Tropical Medicine, London, UK
| | - Sean McGrath
- grid.38142.3c000000041936754XDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA
| | - Lori Rosman
- grid.21107.350000 0001 2171 9311Welch Medical Library, John Hopkins University School of Medicine, Baltimore, USA
| | - Samuel G. Schumacher
- grid.452485.a0000 0001 1507 3147Foundation for Innovative New Diagnostics, Geneva, Switzerland
| | - Andrea Benedetti
- grid.14709.3b0000 0004 1936 8649Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada ,grid.63984.300000 0000 9064 4811Respiratory Epidemiology & Clinical Research Unit, McGill University Health Centre, Montreal, Canada
| | | | - Genevieve Gore
- grid.14709.3b0000 0004 1936 8649Schulich Library of Physical Sciences, Life Sciences, and Engineering, McGill University, Montreal, Canada
| | - Madhukar Pai
- grid.14709.3b0000 0004 1936 8649McGill International TB Centre, McGill University, Montreal, Canada
| | - Hojoon Sohn
- grid.31501.360000 0004 0470 5905Department of Preventive Medicine, College of Medicine, Seoul National University, Seoul, South Korea
| |
Collapse
|
4
|
Engel N, Ochodo EA, Karanja PW, Schmidt BM, Janssen R, Steingart KR, Oliver S. Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views. Cochrane Database Syst Rev 2022; 4:CD014877. [PMID: 35470432 PMCID: PMC9038447 DOI: 10.1002/14651858.cd014877.pub2] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug resistance aim to bring tests closer to the community, and thereby cut delay in diagnosis, ensure early treatment, and improve health outcomes, as well as overcome problems with poor laboratory infrastructure and inadequately trained personnel. Yet, diagnostic technologies only have an impact if they are put to use in a correct and timely manner. Views of the intended beneficiaries are important in uptake of diagnostics, and their effective use also depends on those implementing testing programmes, including providers, laboratory professionals, and staff in health ministries. Otherwise, there is a risk these technologies will not fit their intended use and setting, cannot be made to work and scale up, and are not used by, or not accessible to, those in need. OBJECTIVES To synthesize end-user and professional user perspectives and experiences with low-complexity nucleic acid amplification tests (NAATs) for detection of tuberculosis and tuberculosis drug resistance; and to identify implications for effective implementation and health equity. SEARCH METHODS We searched MEDLINE, Embase, CINAHL, PsycInfo and Science Citation Index Expanded databases for eligible studies from 1 January 2007 up to 20 October 2021. We limited all searches to 2007 onward because the development of Xpert MTB/RIF, the first rapid molecular test in this review, was completed in 2009. SELECTION CRITERIA We included studies that used qualitative methods for data collection and analysis, and were focused on perspectives and experiences of users and potential users of low-complexity NAATs to diagnose tuberculosis and drug-resistant tuberculosis. NAATs included Xpert MTB/RIF, Xpert MTB/RIF Ultra, Xpert MTB/XDR, and the Truenat assays. Users were people with presumptive or confirmed tuberculosis and drug-resistant tuberculosis (including multidrug-resistant (MDR-TB)) and their caregivers, healthcare providers, laboratory technicians and managers, and programme officers and staff; and were from any type of health facility and setting globally. MDR-TB is tuberculosis caused by resistance to at least rifampicin and isoniazid, the two most effective first-line drugs used to treat tuberculosis. DATA COLLECTION AND ANALYSIS We used a thematic analysis approach for data extraction and synthesis, and assessed confidence in the findings using GRADE CERQual approach. We developed a conceptual framework to illustrate how the findings relate. MAIN RESULTS We found 32 studies. All studies were conducted in low- and middle-income countries. Twenty-seven studies were conducted in high-tuberculosis burden countries and 21 studies in high-MDR-TB burden countries. Only one study was from an Eastern European country. While the studies covered a diverse use of low-complexity NAATs, in only a minority of studies was it used as the initial diagnostic test for all people with presumptive tuberculosis. We identified 18 review findings and grouped them into three overarching categories. Critical aspects users value People with tuberculosis valued reaching diagnostic closure with an accurate diagnosis, avoiding diagnostic delays, and keeping diagnostic-associated cost low. Similarly, healthcare providers valued aspects of accuracy and the resulting confidence in low-complexity NAAT results, rapid turnaround times, and keeping cost to people seeking a diagnosis low. In addition, providers valued diversity of sample types (for example, gastric aspirate specimens and stool in children) and drug resistance information. Laboratory professionals appreciated the improved ease of use, ergonomics, and biosafety of low-complexity NAATs compared to sputum microscopy, and increased staff satisfaction. Challenges reported to realizing those values People with tuberculosis and healthcare workers were reluctant to test for tuberculosis (including MDR-TB) due to fears, stigma, or cost concerns. Thus, low-complexity NAAT testing is not implemented with sufficient support or discretion to overcome barriers that are common to other approaches to testing for tuberculosis. Delays were reported at many steps of the diagnostic pathway owing to poor sample quality; difficulties with transporting specimens; lack of sufficient resources; maintenance of low-complexity NAATs; increased workload; inefficient work and patient flows; over-reliance on low-complexity NAAT results in lieu of clinical judgement; and lack of data-driven and inclusive implementation processes. These challenges were reported to lead to underutilization. Concerns for access and equity The reported concerns included sustainable funding and maintenance and equitable use of resources to access low-complexity NAATs, as well as conflicts of interest between donors and people implementing the tests. Also, lengthy diagnostic delays, underutilization of low-complexity NAATs, lack of tuberculosis diagnostic facilities in the community, and too many eligibility restrictions hampered access to prompt and accurate testing and treatment. This was particularly the case for vulnerable groups, such as children, people with MDR-TB, or people with limited ability to pay. We had high confidence in most of our findings. AUTHORS' CONCLUSIONS Low-complexity diagnostics have been presented as a solution to overcome deficiencies in laboratory infrastructure and lack of skilled professionals. This review indicates this is misleading. The lack of infrastructure and human resources undermine the added value new diagnostics of low complexity have for recipients and providers. We had high confidence in the evidence contributing to these review findings. Implementation of new diagnostic technologies, like those considered in this review, will need to tackle the challenges identified in this review including weak infrastructure and systems, and insufficient data on ground level realities prior and during implementation, as well as problems of conflicts of interest in order to ensure equitable use of resources.
Collapse
Affiliation(s)
- Nora Engel
- Department of Health, Ethics & Society, School of Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands
| | - Eleanor A Ochodo
- Centre for Evidence-based Health Care, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
| | | | - Bey-Marrié Schmidt
- School of Public Health, University of the Western Cape, Cape Town, South Africa
| | - Ricky Janssen
- Department of Health, Ethics & Society, School of Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands
| | - Karen R Steingart
- Honorary Research Fellow, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Sandy Oliver
- EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London, London, UK
- Africa Centre for Evidence, Faculty of Humanities, University of Johannesburg, Johannesburg, South Africa
| |
Collapse
|
5
|
Naidoo K, Dookie N. Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing? THE LANCET. INFECTIOUS DISEASES 2022; 22:e121-e127. [PMID: 35227392 DOI: 10.1016/s1473-3099(21)00613-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 09/01/2021] [Accepted: 09/10/2021] [Indexed: 11/26/2022]
Abstract
Early diagnosis, including universal drug-susceptibility testing for all patients with tuberculosis, remains a key priority for tuberculosis elimination by 2035. The drug-resistant tuberculosis care cascade remains persistently challenged by substantial gaps in timely diagnosis and treatment of drug-resistant tuberculosis. Current diagnostics for drug-resistant tuberculosis are limited with respect to accuracy, time to results, affordability, suitability for resource-poor endemic settings, and accessibility for use at the point of care. WHO endorsement of the novel Xpert MTB/XDR assay holds notable promise for expanding access to testing and rapid diagnosis of tuberculosis drug resistance. The Xpert MTB/XDR assay detects resistance to isoniazid, ethionamide, fluoroquinolones, and second-line injectables, and is indicated for testing in patients with confirmed pulmonary tuberculosis. However, this iteration of the Xpert MTB/XDR cartridge might have less of an effect than expected, as WHO has since downgraded the role of second-line injectable agents in treating drug-resistant tuberculosis, and has revised case definitions of drug-resistant tuberculosis to incorporate resistance to new drugs. This Personal View explores the strengths and limitations of the Xpert MTB/XDR assay in the detection of drug resistance, the assay's ability to inform appropriate drug-resistant tuberculosis drug selection, and the optimal placement of the Xpert XDR assay in the laboratory diagnostic workflow.
Collapse
Affiliation(s)
- Kogieleum Naidoo
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; South African Medical Research Council (SAMRC) - CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
| | - Navisha Dookie
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; South African Medical Research Council (SAMRC) - CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa
| |
Collapse
|
6
|
Dookie N, Khan A, Padayatchi N, Naidoo K. Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field. Front Microbiol 2022; 13:775030. [PMID: 35401475 PMCID: PMC8988194 DOI: 10.3389/fmicb.2022.775030] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 02/17/2022] [Indexed: 11/30/2022] Open
Abstract
The World Health Organization’s End TB Strategy prioritizes universal access to an early diagnosis and comprehensive drug susceptibility testing (DST) for all individuals with tuberculosis (TB) as a key component of integrated, patient-centered TB care. Next generation whole genome sequencing (WGS) and its associated technology has demonstrated exceptional potential for reliable and comprehensive resistance prediction for Mycobacterium tuberculosis isolates, allowing for accurate clinical decisions. This review presents a descriptive analysis of research describing the potential of WGS to accelerate delivery of individualized care, recent advances in sputum-based WGS technology and the role of targeted sequencing for resistance detection. We provide an update on recent research describing the mechanisms of resistance to new and repurposed drugs and the dynamics of mixed infections and its potential implication on TB diagnosis and treatment. Whilst the studies reviewed here have greatly improved our understanding of recent advances in this arena, it highlights significant challenges that remain. The wide-spread introduction of new drugs in the absence of standardized DST has led to rapid emergence of drug resistance. This review highlights apparent gaps in our knowledge of the mechanisms contributing to resistance for these new drugs and challenges that limit the clinical utility of next generation sequencing techniques. It is recommended that a combination of genotypic and phenotypic techniques is warranted to monitor treatment response, curb emerging resistance and further dissemination of drug resistance.
Collapse
Affiliation(s)
- Navisha Dookie
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa
- *Correspondence: Navisha Dookie,
| | - Azraa Khan
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa
| | - Nesri Padayatchi
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa
- South African Medical Research Council (SAMRC), CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa
| | - Kogieleum Naidoo
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa
- South African Medical Research Council (SAMRC), CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa
| |
Collapse
|
7
|
Kipiani M, Graciaa DS, Buziashvili M, Darchia L, Avaliani Z, Tabagari N, Mirtskhulava V, Kempker RR. Xpert MTB/RIF Use Is Associated With Earlier Treatment Initiation and Culture Conversion Among Patients With Sputum Smear-Negative Multidrug-Resistant Tuberculosis. Open Forum Infect Dis 2021; 8:ofab551. [PMID: 34877367 PMCID: PMC8643647 DOI: 10.1093/ofid/ofab551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Accepted: 11/03/2021] [Indexed: 11/29/2022] Open
Abstract
Background Although rapid molecular diagnostic tests for tuberculosis (TB) have decreased detection time of Mycobacterium tuberculosis and drug resistance, whether their use improves clinical care and outcomes is uncertain. To address these knowledge gaps, we evaluated whether use of the Xpert MTB/RIF assay impacts treatment and clinical outcome metrics among patients treated for sputum smear-negative multidrug-resistant (MDR)-TB. Methods We conducted a retrospective cohort study of adult patients initiating treatment for sputum smear-negative MDR-TB at the National Center for Tuberculosis and Lung Diseases in Tbilisi, Georgia from 2011 to 2016. The Xpert MTB/RIF was introduced in Georgia in 2010 and implemented into programmatic use in 2014. Exposure was availability of an Xpert result at time of diagnosis. Time to second-line treatment initiation, sputum culture conversion, and end-of-treatment outcomes were determined. Time to event was compared using a Cox proportional hazards model. Results Among 151 patients treated for sputum smear-negative MDR-TB (96% culture positive), the Xpert was utilized in the clinical management of 78 (52%) patients and not used in 73 (48%). An adjusted analysis controlling for potential confounders found that patients in the Xpert group had shorter median time to second-line treatment (13 vs 56 days; adjusted hazard ratio [aHR], 10.21; P < .0001) and culture conversion (61 vs 93 days; aHR, 1.93; P < .001). There was no difference in treatment outcomes. Conclusions Use of the Xpert in the management of sputum smear-negative MDR-TB decreases time to second-line therapy and sputum culture conversion, providing evidence of its clinical impact and supporting its programmatic utility.
Collapse
Affiliation(s)
- Maia Kipiani
- National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.,The University of Georgia, Tbilisi, Georgia
| | - Daniel S Graciaa
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | | | | | - Zaza Avaliani
- National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
| | - Nino Tabagari
- David Tvildiani Medical University, Tbilisi, Georgia
| | | | - Russell R Kempker
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| |
Collapse
|
8
|
Engel N, Ochodo EA, Karanja PW, Schmidt BM, Janssen R, Steingart KR, Oliver S. Rapid molecular tests for tuberculosis and tuberculosis drug resistance: provider and recipient views. Hippokratia 2021. [DOI: 10.1002/14651858.cd014877] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Nora Engel
- Department of Health, Ethics & Society, School of Public Health and Primary Care (CAPHRI); Maastricht University; Maastricht Netherlands
| | - Eleanor A Ochodo
- Centre for Evidence-based Health Care, Department of Global Health, Faculty of Medicine and Health Sciences; Stellenbosch University; Cape Town South Africa
- Centre for Global Health Research; Kenya Medical Research Institute; Kisumu Kenya
| | | | - Bey-Marrié Schmidt
- School of Public Health; University of the Western Cape; Cape Town South Africa
| | - Ricky Janssen
- Department of Health, Ethics & Society, School of Public Health and Primary Care (CAPHRI); Maastricht University; Maastricht Netherlands
| | - Karen R Steingart
- Honorary Research Fellow; Department of Clinical Sciences, Liverpool School of Tropical Medicine; Liverpool UK
| | - Sandy Oliver
- EPPI-Centre, Social Science Research Unit, UCL Institute of Education; University College London; London UK
- Africa Centre for Evidence, Faculty of Humanities; University of Johannesburg; Johannesburg South Africa
| |
Collapse
|
9
|
Nathavitharana RR, Lederer P, Chaplin M, Bjerrum S, Steingart KR, Shah M. Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV. Cochrane Database Syst Rev 2021; 8:CD014641. [PMID: 34416013 PMCID: PMC8407503 DOI: 10.1002/14651858.cd014641] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
BACKGROUND Tuberculosis is the primary cause of hospital admission in people living with HIV, and the likelihood of death in the hospital is unacceptably high. The Alere Determine TB LAM Ag test (AlereLAM) is a point-of-care test and the only lateral flow lipoarabinomannan assay (LF-LAM) assay currently commercially available and recommended by the World Health Organization (WHO). A 2019 Cochrane Review summarised the diagnostic accuracy of LF-LAM for tuberculosis in people living with HIV. This systematic review assesses the impact of the use of LF-LAM (AlereLAM) on mortality and other patient-important outcomes. OBJECTIVES To assess the impact of the use of LF-LAM (AlereLAM) on mortality in adults living with HIV in inpatient and outpatient settings. To assess the impact of the use of LF-LAM (AlereLAM) on other patient-important outcomes in adults living with HIV, including time to diagnosis of tuberculosis, and time to initiation of tuberculosis treatment. SEARCH METHODS We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (PubMed); Embase (Ovid); Science Citation Index Expanded (Web of Science), BIOSIS Previews, Scopus, LILACS; ProQuest Dissertations and Theses; ClinicalTrials.gov; and the WHO ICTRP up to 12 March 2021. SELECTION CRITERIA Randomized controlled trials that compared a diagnostic intervention including LF-LAM with diagnostic strategies that used smear microscopy, mycobacterial culture, a nucleic acid amplification test such as Xpert MTB/RIF, or a combination of these tests. We included adults (≥ 15 years) living with HIV. DATA COLLECTION AND ANALYSIS Two review authors independently assessed trials for eligibility, extracted data, and analysed risk of bias using the Cochrane tool for assessing risk of bias in randomized studies. We contacted study authors for clarification as needed. We used risk ratio (RR) with 95% confidence intervals (CI). We used a fixed-effect model except in the presence of clinical or statistical heterogeneity, in which case we used a random-effects model. We assessed the certainty of the evidence using GRADE. MAIN RESULTS We included three trials, two in inpatient settings and one in outpatient settings. All trials were conducted in sub-Saharan Africa and assessed the impact of diagnostic strategies that included LF-LAM on mortality when the test was used in conjunction with other tuberculosis diagnostic tests or clinical assessment for clinical decision-making in adults living with HIV. Inpatient settings In inpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy likely reduces mortality in people living with HIV at eight weeks compared to routine tuberculosis diagnostic testing without LF-LAM (pooled RR 0.85, 95% CI 0.76 to 0.94; 5102 participants, 2 trials; moderate-certainty evidence). That is, people living with HIV who received LF-LAM had 15% lower risk of mortality. The absolute effect was 34 fewer deaths per 1000 (from 14 fewer to 55 fewer). In inpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy probably results in a slight increase in the proportion of people living with HIV who were started on tuberculosis treatment compared to routine tuberculosis diagnostic testing without LF-LAM (pooled RR 1.26, 95% CI 0.94 to 1.69; 5102 participants, 2 trials; moderate-certainty evidence). Outpatient settings In outpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy may reduce mortality in people living with HIV at six months compared to routine tuberculosis diagnostic testing without LF-LAM (RR 0.89, 95% CI 0.71 to 1.11; 2972 participants, 1 trial; low-certainty evidence). Although this trial did not detect a difference in mortality, the direction of effect was towards a mortality reduction, and the effect size was similar to that in inpatient settings. In outpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy may result in a large increase in the proportion of people living with HIV who were started on tuberculosis treatment compared to routine tuberculosis diagnostic testing without LF-LAM (RR 5.44, 95% CI 4.70 to 6.29, 3022 participants, 1 trial; low-certainty evidence). Other patient-important outcomes Assessment of other patient-important and implementation outcomes in the trials varied. The included trials demonstrated that a higher proportion of people living with HIV were able to produce urine compared to sputum for tuberculosis diagnostic testing; a higher proportion of people living with HIV were diagnosed with tuberculosis in the group that received LF-LAM; and the incremental diagnostic yield was higher for LF-LAM than for urine or sputum Xpert MTB/RIF. AUTHORS' CONCLUSIONS In inpatient settings, the use of LF-LAM as part of a tuberculosis diagnostic testing strategy likely reduces mortality and probably results in a slight increase in tuberculosis treatment initiation in people living with HIV. The reduction in mortality may be due to earlier diagnosis, which facilitates prompt treatment initiation. In outpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy may reduce mortality and may result in a large increase in tuberculosis treatment initiation in people living with HIV. Our results support the implementation of LF-LAM to be used in conjunction with other WHO-recommended tuberculosis diagnostic tests to assist in the rapid diagnosis of tuberculosis in people living with HIV.
Collapse
Affiliation(s)
- Ruvandhi R Nathavitharana
- Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
| | - Philip Lederer
- Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA
| | - Marty Chaplin
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Stephanie Bjerrum
- Department of Clinical Research, Research Unit of Infectious Diseases, University of Southern Denmark, Odense, Denmark
| | - Karen R Steingart
- Honorary Research Fellow, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Maunank Shah
- Department of Medicine, Division of Infectious Diseases, John Hopkins University School of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
10
|
Ochodo EA, Guleid F, Deeks JJ, Mallett S. Point-of-care tests detecting HIV nucleic acids for diagnosis of HIV-1 or HIV-2 infection in infants and children aged 18 months or less. Cochrane Database Syst Rev 2021; 8:CD013207. [PMID: 34383961 PMCID: PMC8406580 DOI: 10.1002/14651858.cd013207.pub2] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND The standard method of diagnosing HIV in infants and children less than 18 months is with a nucleic acid amplification test reverse transcriptase polymerase chain reaction test (NAT RT-PCR) detecting viral ribonucleic acid (RNA). Laboratory testing using the RT-PCR platform for HIV infection is limited by poor access, logistical support, and delays in relaying test results and initiating therapy in low-resource settings. The use of rapid diagnostic tests at or near the point-of-care (POC) can increase access to early diagnosis of HIV infection in infants and children less than 18 months of age and timely initiation of antiretroviral therapy (ART). OBJECTIVES To summarize the diagnostic accuracy of point-of-care nucleic acid-based testing (POC NAT) to detect HIV-1/HIV-2 infection in infants and children aged 18 months or less exposed to HIV infection. SEARCH METHODS We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (until 2 February 2021), MEDLINE and Embase (until 1 February 2021), and LILACS and Web of Science (until 2 February 2021) with no language or publication status restriction. We also searched conference websites and clinical trial registries, tracked reference lists of included studies and relevant systematic reviews, and consulted experts for potentially eligible studies. SELECTION CRITERIA We defined POC tests as rapid diagnostic tests conducted at or near the patient site. We included any primary study that compared the results of a POC NAT to a reference standard of laboratory NAT RT-PCR or total nucleic acid testing to detect the presence or absence of HIV infection denoted by HIV viral nucleic acids in infants and children aged 18 months or less who were exposed to HIV-1/HIV-2 infection. We included cross-sectional, prospective, and retrospective study designs and those that provided sufficient data to create the 2 × 2 table to calculate sensitivity and specificity. We excluded diagnostic case control studies with healthy controls. DATA COLLECTION AND ANALYSIS We extracted information on study characteristics using a pretested standardized data extraction form. We used the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) tool to assess the risk of bias and applicability concerns of the included studies. Two review authors independently selected and assessed the included studies, resolving any disagreements by consensus. The unit of analysis was the participant. We first conducted preliminary exploratory analyses by plotting estimates of sensitivity and specificity from each study on forest plots and in receiver operating characteristic (ROC) space. For the overall meta-analyses, we pooled estimates of sensitivity and specificity using the bivariate meta-analysis model at a common threshold (presence or absence of infection). MAIN RESULTS We identified a total of 12 studies (15 evaluations, 15,120 participants). All studies were conducted in sub-Saharan Africa. The ages of included infants and children in the evaluations were as follows: at birth (n = 6), ≤ 12 months (n = 3), ≤ 18 months (n = 5), and ≤ 24 months (n = 1). Ten evaluations were field evaluations of the POC NAT test at the point of care, and five were laboratory evaluations of the POC NAT tests.The POC NAT tests evaluated included Alere q HIV-1/2 Detect qualitative test (recently renamed m-PIMA q HIV-1/2 Detect qualitative test) (n = 6), Xpert HIV-1 qualitative test (n = 6), and SAMBA HIV-1 qualitative test (n = 3). POC NAT pooled sensitivity and specificity (95% confidence interval (CI)) against laboratory reference standard tests were 98.6% (96.1 to 99.5) (15 evaluations, 1728 participants) and 99.9% (99.7 to 99.9) (15 evaluations, 13,392 participants) in infants and children ≤ 18 months. Risk of bias in the included studies was mostly low or unclear due to poor reporting. Five evaluations had some concerns for applicability for the index test, as they were POC tests evaluated in a laboratory setting, but there was no difference detected between settings in sensitivity (-1.3% (95% CI -4.1 to 1.5)); and specificity results were similar. AUTHORS' CONCLUSIONS For the diagnosis of HIV-1/HIV-2 infection, we found the sensitivity and specificity of POC NAT tests to be high in infants and children aged 18 months or less who were exposed to HIV infection.
Collapse
Affiliation(s)
- Eleanor A Ochodo
- Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
- Centre for Evidence-based Health Care, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Fatuma Guleid
- KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
| | - Jonathan J Deeks
- Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK
| | - Sue Mallett
- UCL Centre for Medical Imaging, Division of Medicine, Faculty of Medical Sciences, University College London, London, UK
| |
Collapse
|
11
|
Haraka F, Kakolwa M, Schumacher SG, Nathavitharana RR, Denkinger CM, Gagneux S, Reither K, Ross A. Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis. Cochrane Database Syst Rev 2021; 5:CD012972. [PMID: 34097769 PMCID: PMC8208889 DOI: 10.1002/14651858.cd012972.pub2] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
BACKGROUND The World Health Organization (WHO) recommends Xpert MTB/RIF in place of smear microscopy to diagnose tuberculosis (TB), and many countries have adopted it into their diagnostic algorithms. However, it is not clear whether the greater accuracy of the test translates into improved health outcomes. OBJECTIVES To assess the impact of Xpert MTB/RIF on patient outcomes in people being investigated for tuberculosis. SEARCH METHODS We searched the following databases, without language restriction, from 2007 to 24 July 2020: Cochrane Infectious Disease Group (CIDG) Specialized Register; CENTRAL; MEDLINE OVID; Embase OVID; CINAHL EBSCO; LILACS BIREME; Science Citation Index Expanded (Web of Science), Social Sciences citation index (Web of Science), and Conference Proceedings Citation Index - Social Science & Humanities (Web of Science). We also searched the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, and the Pan African Clinical Trials Registry for ongoing trials. SELECTION CRITERIA We included individual- and cluster-randomized trials, and before-after studies, in participants being investigated for tuberculosis. We analysed the randomized and non-randomized studies separately. DATA COLLECTION AND ANALYSIS: For each study, two review authors independently extracted data, using a piloted data extraction tool. We assessed the risk of bias using Cochrane and Effective Practice and Organisation of Care (EPOC) tools. We used random effects meta-analysis to allow for heterogeneity between studies in setting and design. The certainty of the evidence in the randomized trials was assessed by GRADE. MAIN RESULTS We included 12 studies: eight were randomized controlled trials (RCTs), and four were before-and-after studies. Most included RCTs had a low risk of bias in most domains of the Cochrane 'Risk of bias' tool. There was inconclusive evidence of an effect of Xpert MTB/RIF on all-cause mortality, both overall (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.75 to 1.05; 5 RCTs, 9932 participants, moderate-certainty evidence), and restricted to studies with six-month follow-up (RR 0.98, 95% CI 0.78 to 1.22; 3 RCTs, 8143 participants; moderate-certainty evidence). There was probably a reduction in mortality in participants known to be infected with HIV (odds ratio (OR) 0.80, 95% CI 0.67 to 0.96; 5 RCTs, 5855 participants; moderate-certainty evidence). It is uncertain whether Xpert MTB/RIF has no or a modest effect on the proportion of participants starting tuberculosis treatment who had a successful treatment outcome (OR) 1.10, 95% CI 0.96 to 1.26; 3RCTs, 4802 participants; moderate-certainty evidence). There was also inconclusive evidence of an effect on the proportion of participants who were treated for tuberculosis (RR 1.10, 95% CI 0.98 to 1.23; 5 RCTs, 8793 participants; moderate-certainty evidence). The proportion of participants treated for tuberculosis who had bacteriological confirmation was probably higher in the Xpert MTB/RIF group (RR 1.44, 95% CI 1.29 to 1.61; 6 RCTs, 2068 participants; moderate-certainty evidence). The proportion of participants with bacteriological confirmation who were lost to follow-up pre-treatment was probably reduced (RR 0.59, 95% CI 0.41 to 0.85; 3 RCTs, 1217 participants; moderate-certainty evidence). AUTHORS' CONCLUSIONS We were unable to confidently rule in or rule out the effect on all-cause mortality of using Xpert MTB/RIF rather than smear microscopy. Xpert MTB/RIF probably reduces mortality among participants known to be infected with HIV. We are uncertain whether Xpert MTB/RIF has a modest effect or not on the proportion treated or, among those treated, on the proportion with a successful outcome. It probably does not have a substantial effect on these outcomes. Xpert MTB/RIF probably increases both the proportion of treated participants who had bacteriological confirmation, and the proportion with a laboratory-confirmed diagnosis who were treated. These findings may inform decisions about uptake alongside evidence on cost-effectiveness and implementation.
Collapse
Affiliation(s)
- Frederick Haraka
- Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania
- Ifakara Health Institute, Bagamoyo, Tanzania
- University of Basel, Basel, Switzerland
- Swiss Tropical and Public Health Institute, Basel, Switzerland
| | | | | | - Ruvandhi R Nathavitharana
- Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
| | - Claudia M Denkinger
- FIND, Geneva, Switzerland
- Division of Tropical Medicine, Centre for Infectious Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - Sebastien Gagneux
- University of Basel, Basel, Switzerland
- Swiss Tropical and Public Health Institute, Basel, Switzerland
| | - Klaus Reither
- Ifakara Health Institute, Bagamoyo, Tanzania
- University of Basel, Basel, Switzerland
- Swiss Tropical and Public Health Institute, Basel, Switzerland
| | - Amanda Ross
- University of Basel, Basel, Switzerland
- Swiss Tropical and Public Health Institute, Basel, Switzerland
| |
Collapse
|
12
|
Banaei N, Musser KA, Salfinger M, Somoskovi A, Zelazny AM. Novel Assays/Applications for Patients Suspected of Mycobacterial Diseases. Clin Lab Med 2020; 40:535-552. [DOI: 10.1016/j.cll.2020.08.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
13
|
Abstract
Molecular tests for tuberculosis (TB) have the potential to help reach the three million people with TB who are undiagnosed or not reported each year and to improve the quality of care TB patients receive by providing accurate, quick results, including rapid drug-susceptibility testing. The World Health Organization (WHO) has recommended the use of molecular nucleic acid amplification tests (NAATs) tests for TB detection instead of smear microscopy, as they are able to detect TB more accurately, particularly in patients with paucibacillary disease and in people living with HIV. Importantly, some of these WHO-endorsed tests can detect mycobacterial gene mutations associated with anti-TB drug resistance, allowing clinicians to tailor effective TB treatment. Currently, a wide array of molecular tests for TB detection is being developed and evaluated, and while some tests are intended for reference laboratory use, others are being aimed at the point-of-care and peripheral health care settings. Notably, there is an emergence of molecular tests designed, manufactured, and rolled out in countries with high TB burden, of which some are explicitly aimed for near-patient placement. These developments should increase access to molecular TB testing for larger patient populations. With respect to drug susceptibility testing, NAATs and next-generation sequencing can provide results substantially faster than traditional phenotypic culture. Here, we review recent advances and developments in molecular tests for detecting TB as well as anti-TB drug resistance.
Collapse
|
14
|
Ochodo EA, Kalema N, Schumacher S, Steingart K, Young T, Mallett S, Deeks J, Cobelens F, Bossuyt PM, Nicol MP, Cattamanchi A. Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. Wellcome Open Res 2020; 4:173. [PMID: 32851196 PMCID: PMC7438967 DOI: 10.12688/wellcomeopenres.15412.2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/06/2020] [Indexed: 12/21/2022] Open
Abstract
Background: Most studies evaluating the effect of Xpert MTB/RIF testing for tuberculosis (TB) concluded that it did not reduce overall mortality compared to usual care. We conducted a systematic review to assess whether key study design and execution features contributed to earlier identification of patients with TB and decreased pre-treatment loss to follow-up, thereby reducing the potential impact of Xpert MTB/RIF testing. Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Scopus for literature published from 1 st January 2009 to February 2019. We included all primary intervention studies that had evaluated the effect of Xpert MTB/RIF on mortality compared to usual care in participants with presumptive pulmonary TB. We critically reviewed features of included studies across: Study setting and context, Study population, Participant recruitment and enrolment, Study procedures, and Study follow-up. Results: We included seven randomised and one non-randomised study. All included studies demonstrated relative reductions in overall mortality in the Xpert MTB/RIF arm ranging from 6% to 40%. However, mortality reduction was reported to be statistically significant in two studies. Study features that could explain the lack of observed effect on mortality included: the higher quality of care at study sites; inclusion of patients with a higher pre-test probability of TB leading to higher than expected empirical rates; performance of additional diagnostic testing not done in usual care leading to increased TB diagnosis or empiric treatment initiation; the recruitment of participants likely to return for follow-up; and involvement of study staff in ensuring adherence with care and follow-up. Conclusion: Most studies of Xpert MTB/RIF were designed and conducted in a manner that resulted in more patients being diagnosed and treated for TB, minimising the potential difference in mortality Xpert MTB/RIF testing could have achieved compared to usual care.
Collapse
Affiliation(s)
- Eleanor A. Ochodo
- Department of Global Health, Stellenbosch University, Cape Town, Western Cape, 8000, South Africa
| | - Nelson Kalema
- Infectious Diseases Institute, Makerere University, Kampala, 22418, Uganda
| | - Samuel Schumacher
- Tuberculosis Department, Foundation for Innovative New Diagnostics, Geneva, 1202, Switzerland
| | - Karen Steingart
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK
| | - Taryn Young
- Department of Global Health, Stellenbosch University, Cape Town, Western Cape, 8000, South Africa
| | - Susan Mallett
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Trust, University of Birmingham, Edgbaston, Birmingham, UK
- Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK
| | - Jon Deeks
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Trust, University of Birmingham, Edgbaston, Birmingham, UK
- Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK
| | - Frank Cobelens
- Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Amsterdam, 1105 BP, The Netherlands
| | - Patrick M. Bossuyt
- Deapartment of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands
| | - Mark P. Nicol
- School of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, 6009, Australia
| | - Adithya Cattamanchi
- Division of Pulmonary and Critical Care Medicine, University of California San Francisco Medical Center, San Francisco, California, 94110, USA
| |
Collapse
|
15
|
Kersting C, Kneer M, Barzel A. Patient-relevant outcomes: what are we talking about? A scoping review to improve conceptual clarity. BMC Health Serv Res 2020; 20:596. [PMID: 32600321 PMCID: PMC7325243 DOI: 10.1186/s12913-020-05442-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Accepted: 06/18/2020] [Indexed: 12/21/2022] Open
Abstract
Background With respect to patient-centered care, measuring care effects based on patient-relevant outcomes is becoming increasingly important. There is some uncertainty about what outcomes are particularly relevant to patients and who determines their relevance. To determine this, we conducted a scoping review of the international literature with the aim to improve the conceptual clarity regarding (1) the terminology used for supposedly patient-relevant outcomes, (2) the variety of outcomes considered patient-relevant, and (3) justifications for the choice of these specific outcomes. Methods We conducted a systematic search in Embase, PubMed (including Medline), Cochrane Central, Scopus, and Google Scholar with a special focus on article titles. Search terms included patient-relevant, patient-important, patient-preferred, and outcome(s), endpoint(s), parameter(s), indicator(s). We limited the search period from January 2000 to July 2019. Full-text articles reporting outcomes that were described as patient-relevant met the inclusion criteria. Two researchers independently analyzed all eligible articles applying quantitative and structuring content analysis. Results We identified 155 articles, 44 of which met the inclusion criteria. A content analysis revealed 35 different terms used with regard to patient-relevant outcomes. However, authors predominantly referred to patient-important outcomes (23 articles, 52.3%) and patient-relevant outcomes (17 articles, 38.6%). A structuring content analysis of all extracted outcomes revealed a total of 281 codes, pooled in 32 inductive categories. Among these, the following categories dominated: symptoms, adverse events/complications, survival/mortality, pain. In just 16 of the articles (36.4%), authors provided justifications for the choice of the outcome being based either on patient and/or expert opinions. In another 13 articles (29.5%), no justification was provided. Conclusion This scoping review on patient-relevant outcomes was driven by the questions (1) what outcomes are particularly relevant to patients, and (2) who determines their relevance. We found a wide range of supposedly patient-relevant outcomes, with only one third of articles involving patients in the justification of the outcome selection. In view of this conceptual uncertainty it appears difficult to determine or even to compare a particular patient benefit of interventions. A set of generic outcomes relevant to patients would be helpful to contribute to a consistent understanding of patient relevance.
Collapse
Affiliation(s)
- Christine Kersting
- Institute of General Practice and Interprofessional Care, Faculty of Health/School of Medicine, Witten/Herdecke University, Alfred-Herrhausen-Str. 50, 58448, Witten, Germany.
| | - Malte Kneer
- Institute of General Practice and Interprofessional Care, Faculty of Health/School of Medicine, Witten/Herdecke University, Alfred-Herrhausen-Str. 50, 58448, Witten, Germany
| | - Anne Barzel
- Institute of General Practice and Interprofessional Care, Faculty of Health/School of Medicine, Witten/Herdecke University, Alfred-Herrhausen-Str. 50, 58448, Witten, Germany.,Institute of General Medicine, Ulm University, Albert-Einstein-Allee 23, 89081, Ulm, Germany
| |
Collapse
|
16
|
Agizew T, Boyd R, Auld AF, Payton L, Pals SL, Lekone P, Chihota V, Finlay A. Treatment outcomes, diagnostic and therapeutic impact: Xpert vs. smear. A systematic review and meta-analysis. Int J Tuberc Lung Dis 2019; 23:82-92. [PMID: 30674379 DOI: 10.5588/ijtld.18.0203] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Compared with smear microscopy, Xpert® MTB/RIF has the potential to reduce delays in tuberculosis (TB) diagnosis and treatment initiation, and improve treatment outcomes. We reviewed publications comparing treatment outcomes of drug-susceptible TB patients diagnosed using Xpert vs. smear. METHODS Citations (2000-2016) reporting treatment outcomes of patients diagnosed using Xpert compared with smear were selected from PubMed, Scopus and conference abstracts. We conducted a systematic review and meta-analysis. Favorable (cured, completed) and unfavorable (failure, death, loss to follow-up) outcomes were pooled for meta-analysis; we also reviewed the number of TB cases diagnosed, time to treatment and empiric treatment. The Mantel-Haenszel method with a fixed-effect model was used; I² was calculated to measure heterogeneity. RESULTS From 13 citations, 43 594 TB patients were included and 4825 were with known TB treatment outcome. From the pooled analysis, an unfavorable outcomes among those diagnosed using Xpert compared with smear was 20.2%, 541/2675 vs. 21.9%, 470/2150 (risk ratio 0.92, 95%CI 0.82-1.02). Statistical heterogeneity was low (I² = 0.0%, P = 0.910). Compared with smear, Xpert was reported to be superior in increasing the number of TB patients diagnosed (2/9 citations), increasing bacteriologically confirmed TB (7/9 citations), reducing empiric treatment (3/5 citations), reducing time to diagnosis (2/3 citations), and reducing time to treatment initiation (1/5 citations). CONCLUSIONS Xpert implementation showed no discernible impact on treatment outcomes compared with conventional smear despite reduced time to diagnosis, time to treatment or reduced level of empiric treatment. Further research is required to learn more about gaps in the existing health system.
Collapse
Affiliation(s)
- T Agizew
- Centers for Disease Control and Prevention (CDC), Gaborone, Botswana, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, Faculty of Medicine, University of Botswana, Gaborone, Botswana
| | - R Boyd
- Centers for Disease Control and Prevention (CDC), Gaborone, Botswana, Division of Tuberculosis Elimination
| | - A F Auld
- Division of Global HIV and Tuberculosis, CDC, Atlanta, Georgia, USA
| | - L Payton
- Centers for Disease Control and Prevention (CDC), Gaborone, Botswana
| | - S L Pals
- Division of Global HIV and Tuberculosis, CDC, Atlanta, Georgia, USA
| | - P Lekone
- Centers for Disease Control and Prevention (CDC), Gaborone, Botswana
| | - V Chihota
- Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, Aurum Institute, Johannesburg, South Africa
| | - A Finlay
- Centers for Disease Control and Prevention (CDC), Gaborone, Botswana, Division of Tuberculosis Elimination
| |
Collapse
|
17
|
Ochodo EA, Naidoo S, Schumacher S, Steingart K, Deeks J, Cobelens F, Bossuyt PM, Young T, Nicol MP. Improving the design of studies evaluating the impact of diagnostic tests for tuberculosis on health outcomes: a qualitative study of perspectives of diverse stakeholders. Wellcome Open Res 2019; 4:183. [PMID: 32133421 PMCID: PMC7041361 DOI: 10.12688/wellcomeopenres.15551.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/18/2019] [Indexed: 11/20/2022] Open
Abstract
Background: Studies evaluating the impact of Xpert MTB/RIF testing for tuberculosis (TB) have demonstrated varied effects on health outcomes with many studies showing inconclusive results. We explored perceptions among diverse stakeholders about studies evaluating the impact of TB diagnostic tests, and identified suggestions for improving these studies. Methods: We used purposive sampling with consideration for differing expertise and geographical balance and conducted in depth semi-structured interviews. We interviewed English-speaking participants, including TB patients, and others involved in research, care or decision-making about TB diagnostics. We used the thematic approach to code and analyse the interview transcripts. Results: We interviewed 31 participants. Our study showed that stakeholders had different expectations with regard to test impact and how it is measured. TB test impact studies were perceived to be important for supporting implementation of tests but there were concerns about the unrealistic expectations placed on tests to improve outcomes in health systems with many influencing factors. To improve TB test impact studies, respondents suggested conducting health system assessments prior to the study; developing clear guidance on the study methodology and interpretation; improving study design by describing questions and interventions that consider the influences of the health-care ecosystem on the diagnostic test; selecting the target population at the health-care level most likely to benefit from the test; setting realistic targets for effect sizes in the sample size calculations; and interpreting study results carefully and avoiding categorisation and interpretation of results based on statistical significance alone. Researchers should involve multiple stakeholders in the design of studies. Advocating for more funding to support robust studies is essential. Conclusion: TB test impact studies were perceived to be important to support implementation of tests but there were concerns about their complexity. Process evaluations of their health system context and guidance for their design and interpretation are recommended.
Collapse
Affiliation(s)
- Eleanor A. Ochodo
- Centre for Evidence-based Health Care, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, Western Cape, 8000, South Africa
| | - Selvan Naidoo
- Centre for Evidence-based Health Care, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, Western Cape, 8000, South Africa
| | - Samuel Schumacher
- Tuberculosis department, Campus Biotech, Foundation for Innovative New Diagnostics, Geneva, 1202, Switzerland
| | - Karen Steingart
- Clinical sciences, Liverpool School of Tropical Medicine, Liverpool, L3 5QA UK, UK
| | - Jon Deeks
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Trust and University of Birmingham; and Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
| | - Frank Cobelens
- Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Amsterdam, 1105 BP, The Netherlands
| | - Patrick M. Bossuyt
- Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam Public Health research institute, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands
| | - Taryn Young
- Centre for Evidence-based Health Care, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, Western Cape, 8000, South Africa
| | - Mark P. Nicol
- School of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA 6009, Australia
| |
Collapse
|
18
|
Ochodo EA, Kalema N, Schumacher S, Steingart K, Young T, Mallett S, Deeks J, Cobelens F, Bossuyt PM, Nicol MP, Cattamanchi A. Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. Wellcome Open Res 2019; 4:173. [PMID: 32851196 PMCID: PMC7438967 DOI: 10.12688/wellcomeopenres.15412.1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/16/2019] [Indexed: 02/15/2024] Open
Abstract
Background: Most studies evaluating the effect of Xpert MTB/RIF testing for tuberculosis (TB) concluded that it did not reduce overall mortality compared to usual care. We conducted a systematic review to assess whether key study design and execution features contributed to earlier identification of patients with TB and decreased pre-treatment loss to follow-up, thereby reducing the potential impact of Xpert MTB/RIF testing. Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Scopus for literature published from 1 st January 2009 to February 2019. We included all primary intervention studies that had evaluated the effect of Xpert MTB/RIF on mortality compared to usual care in participants with presumptive pulmonary TB. We critically reviewed features of included studies across: Study setting and context, Study population, Participant recruitment and enrolment, Study procedures, and Study follow-up. Results: We included seven randomised and one non-randomised study. All included studies demonstrated relative reductions in overall mortality in the Xpert MTB/RIF arm ranging from 6% to 40%. However, mortality reduction was reported to be statistically significant in two studies. Study features that could explain the lack of observed effect on mortality included: the higher quality of care at study sites; inclusion of patients with a higher pre-test probability of TB leading to higher than expected empirical rates; performance of additional diagnostic testing not done in usual care leading to increased TB diagnosis or empiric treatment initiation; the recruitment of participants likely to return for follow-up; and involvement of study staff in ensuring adherence with care and follow-up. Conclusion: Most studies of Xpert MTB/RIF were designed and conducted in a manner that resulted in more patients being diagnosed and treated for TB, minimising the potential difference in mortality Xpert MTB/RIF testing could have achieved compared to usual care.
Collapse
Affiliation(s)
- Eleanor A. Ochodo
- Department of Global Health, Stellenbosch University, Cape Town, Western Cape, 8000, South Africa
| | - Nelson Kalema
- Infectious Diseases Institute, Makerere University, Kampala, 22418, Uganda
| | - Samuel Schumacher
- Tuberculosis Department, Foundation for Innovative New Diagnostics, Geneva, 1202, Switzerland
| | - Karen Steingart
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK
| | - Taryn Young
- Department of Global Health, Stellenbosch University, Cape Town, Western Cape, 8000, South Africa
| | - Susan Mallett
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Trust, University of Birmingham, Edgbaston, Birmingham, UK
- Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK
| | - Jon Deeks
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Trust, University of Birmingham, Edgbaston, Birmingham, UK
- Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK
| | - Frank Cobelens
- Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Amsterdam, 1105 BP, The Netherlands
| | - Patrick M. Bossuyt
- Deapartment of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, Amsterdam, 1105 AZ, The Netherlands
| | - Mark P. Nicol
- School of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, 6009, Australia
| | - Adithya Cattamanchi
- Division of Pulmonary and Critical Care Medicine, University of California San Francisco Medical Center, San Francisco, California, 94110, USA
| |
Collapse
|
19
|
Schumacher SG, Wells WA, Nicol MP, Steingart KR, Theron G, Dorman SE, Pai M, Churchyard G, Scott L, Stevens W, Nabeta P, Alland D, Weyer K, Denkinger CM, Gilpin C. Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. J Infect Dis 2019; 220:S99-S107. [PMID: 31593597 PMCID: PMC6782025 DOI: 10.1093/infdis/jiz258] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Tests that can replace sputum smear microscopy have been identified as a top priority diagnostic need for tuberculosis by the World Health Organization. High-quality evidence on diagnostic accuracy for tests that may meet this need is an essential requirement to inform decisions about policy and scale-up. However, test accuracy studies are often of low and inconsistent quality and poorly reported, leading to uncertainty about true test performance. Here we provide guidance for the design of diagnostic test accuracy studies of sputum smear-replacement tests. Such studies should have a cross-sectional or cohort design, enrolling either a consecutive series or a random sample of patients who require evaluation for tuberculosis. Adults with respiratory symptoms are the target population. The reference standard should at a minimum be a single, automated, liquid culture, but additional cultures, follow-up, clinical case definition, and specific measures to understand discordant results should also be included. Inclusion of smear microscopy and Xpert MTB/RIF (or MTB/RIF Ultra) as comparators is critical to allow broader comparability and generalizability of results, because disease spectrum can vary between studies and affects relative test performance. Given the complex nature of sputum (the primary specimen type used for pulmonary TB), careful design and reporting of the specimen flow is essential. Test characteristics other than accuracy (such as feasibility, implementation considerations, and data on impact on patient, population and health systems outcomes) are also important aspects.
Collapse
Affiliation(s)
| | - William A Wells
- United States Agency for International Development, Washington, District of Columbia
| | - Mark P Nicol
- School of Biomedical Sciences, University of Western Australia, Perth, Australia, United Kingdom
| | | | - Grant Theron
- DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, SA MRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa
| | | | - Madhukar Pai
- McGill International TB Centre and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada
| | - Gavin Churchyard
- Aurum Institute, Cape Town, South Africa
- School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
- Advancing Care and Treatment for TB/HIV, South African Medical Research Council, Parktown, South Africa
| | - Lesley Scott
- University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa
| | - Wendy Stevens
- University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa
| | | | | | - Karin Weyer
- World Health Organization, Geneva, Switzerland
| | - Claudia M Denkinger
- FIND, Geneva, Switzerland
- University Hospital Heidelberg, Division of Tropical Medicine, Centre of Infectious Diseases, Germany
| | | |
Collapse
|
20
|
Marks GB, Nguyen NV, Nguyen PTB, Nguyen TA, Nguyen HB, Tran KH, Nguyen SV, Luu KB, Tran DTT, Vo QTN, Le OTT, Nguyen YH, Do VQ, Mason PH, Nguyen VAT, Ho J, Sintchenko V, Nguyen LN, Britton WJ, Fox GJ. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. N Engl J Med 2019; 381:1347-1357. [PMID: 31577876 DOI: 10.1056/nejmoa1902129] [Citation(s) in RCA: 100] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND The World Health Organization has set ambitious targets for the global elimination of tuberculosis. However, these targets will not be achieved at the current rate of progress. METHODS We performed a cluster-randomized, controlled trial in Ca Mau Province, Vietnam, to evaluate the effectiveness of active community-wide screening, as compared with standard passive case detection alone, for reducing the prevalence of tuberculosis. Persons 15 years of age or older who resided in 60 intervention clusters (subcommunes) were screened for pulmonary tuberculosis, regardless of symptoms, annually for 3 years, beginning in 2014, by means of rapid nucleic acid amplification testing of spontaneously expectorated sputum samples. Active screening was not performed in the 60 control clusters in the first 3 years. The primary outcome, measured in the fourth year, was the prevalence of microbiologically confirmed pulmonary tuberculosis among persons 15 years of age or older. The secondary outcome was the prevalence of tuberculosis infection, as assessed by an interferon gamma release assay in the fourth year, among children born in 2012. RESULTS In the fourth-year prevalence survey, we tested 42,150 participants in the intervention group and 41,680 participants in the control group. A total of 53 participants in the intervention group (126 per 100,000 population) and 94 participants in the control group (226 per 100,000) had pulmonary tuberculosis, as confirmed by a positive nucleic acid amplification test for Mycobacterium tuberculosis (prevalence ratio, 0.56; 95% confidence interval [CI], 0.40 to 0.78; P<0.001). The prevalence of tuberculosis infection in children born in 2012 was 3.3% in the intervention group and 2.6% in the control group (prevalence ratio, 1.29; 95% CI, 0.70 to 2.36; P = 0.42). CONCLUSIONS Three years of community-wide screening in persons 15 years of age or older who resided in Ca Mau Province, Vietnam, resulted in a lower prevalence of pulmonary tuberculosis in the fourth year than standard passive case detection alone. (Funded by the Australian National Health and Medical Research Council; ACT3 Australian New Zealand Clinical Trials Registry number, ACTRN12614000372684.).
Collapse
Affiliation(s)
- Guy B Marks
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Nhung V Nguyen
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Phuong T B Nguyen
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Thu-Anh Nguyen
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Hoa B Nguyen
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Khoa H Tran
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Son V Nguyen
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Khanh B Luu
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Duc T T Tran
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Qui T N Vo
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Oanh T T Le
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Yen H Nguyen
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Vu Q Do
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Paul H Mason
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Van-Anh T Nguyen
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Jennifer Ho
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Vitali Sintchenko
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Linh N Nguyen
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Warwick J Britton
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| | - Greg J Fox
- From the Woolcock Institute of Medical Research (G.B.M., P.T.B.N., T.-A.N., K.B.L., D.T.T.T., Q.T.N.V., O.T.T.L., Y.H.N., P.H.M., J.H., G.J.F.), the National Lung Hospital (N.V.N., H.B.N.), the National Institute of Hygiene and Epidemiology (V.-A.T.N..), and the National Tuberculosis Control Program (N.V.N., H.B.N., K.H.T., S.V.N.), Hanoi, and the Center for Social Disease Control, Ca Mau (K.H.T., S.V.N.) - all in Vietnam; the South Western Sydney Clinical School, University of New South Wales (G.B.M., J.H.), and the Faculty of Medicine and Health (G.B.M., N.V.N., T.-A.N., V.Q.D., P.H.M., V.S., W.J.B., G.J.F.) and the Centenary Institute (W.J.B.), University of Sydney, Sydney, the School of Social Sciences, Monash, Clayton, VIC (P.H.M.), and the Department of Anthropology, Macquarie University, North Ryde, NSW (P.H.M.) - all in Australia; the Center for Operational Research, International Union against Tuberculosis and Lung Disease, Paris (H.B.N.); and the Global Tuberculosis Program, World Health Organization, Geneva (L.N.N.)
| |
Collapse
|
21
|
Banamu JK, Lavu E, Johnson K, Moke R, Majumdar SS, Takarinda KC, Commons RJ. Impact of GxAlert on the management of rifampicin-resistant tuberculosis patients, Port Moresby, Papua New Guinea. Public Health Action 2019; 9:S19-S24. [PMID: 31579645 DOI: 10.5588/pha.18.0067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Accepted: 10/23/2018] [Indexed: 11/10/2022] Open
Abstract
Setting GxAlert is an automatic electronic notification service that provides immediate Xpert® MTB/RIF testing results. It was implemented for the notification of patients with rifampicin resistant-tuberculosis (RR-TB) at Port Moresby General Hospital, Port Moresby, Papua New Guinea, in May 2015. Objective To determine if there were differences in pre-treatment attrition, the time to treatment initiation and patient outcomes in the 12 months pre- and post-introduction of GxAlert for RR-TB patients. Design This was a retrospective cohort study. Results The median time from Xpert testing to treatment initiation decreased from 35 days [IQR 13-131] prior to GxAlert to 10 days [IQR 3-29] after GxAlert (P = 0.001), with the cumulative proportion of patients initiating treatment within 30 days increasing from 25% (95%CI 17-37) to 54% (95%CI 44-64; P < 0.001) over these periods. However, our analysis of the time to treatment prior to the introduction of GxAlert suggests that a decrease had already occurred prior to implementation. There was no difference in interim clinical outcomes between the periods. Conclusion Although a decrease in time to treatment initiation cannot be attributed to GxAlert, there was a significant improvement over the 2-year period, suggesting that considerable improvements have been made in timely RR-TB patient management in Port Moresby.
Collapse
Affiliation(s)
- J K Banamu
- Central Public Health Laboratory, Port Moresby, Papua New Guinea (PNG)
| | - E Lavu
- Central Public Health Laboratory, Port Moresby, Papua New Guinea (PNG)
| | - K Johnson
- Central Public Health Laboratory, Port Moresby, Papua New Guinea (PNG).,Health and HIV Implementation Services Provider, Port Morseby, PNG
| | - R Moke
- Internal Medicine Division, Port Moresby General Hospital, Port Moresby, PNG
| | - S S Majumdar
- Burnet Institute, Melbourne, Victoria, Australia
| | - K C Takarinda
- The International Union Against Tuberculosis and Lung Disease, Paris, France
| | - R J Commons
- Burnet Institute, Melbourne, Victoria, Australia.,Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
| |
Collapse
|
22
|
Mason PH, Lyttleton C, Marks GB, Fox GJ. The technological imperative in tuberculosis care and prevention in Vietnam. Glob Public Health 2019; 15:307-320. [PMID: 31422743 DOI: 10.1080/17441692.2019.1650950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
A monocausal bacteriological understanding of infectious disease orients tuberculosis control efforts towards antimicrobial interventions. A bias towards technological solutions can leave multistranded public health and social interventions largely neglected. In the context of globalising biomedical approaches to infectious disease control, this ethnography-inspired review article reflects upon the implementation of rapid diagnostic technology in low- and middle-income countries. Fieldwork observations in Vietnam provided a stimulus for a critical review of the global rollout of tuberculosis diagnostic technology. To address local needs in tuberculosis control, health managers in resource-poor settings are readily cooperating with international donors to deploy novel diagnostic technologies throughout national tuberculosis programme facilities. Increasing investment in new diagnostic technologies is predicated on the supposition that these interventions will ameliorate disease outcomes. However, suboptimal treatment control persists even when accurate diagnostic technologies are available, suggesting that promotion of singular technological solutions can distract from addressing systemic change, without which disease susceptibility, propagation of infection, detection gaps, diagnostic delays, and treatment shortfalls persist.
Collapse
Affiliation(s)
- Paul H Mason
- NHMRC Tuberculosis Centre of Research Excellence, Australia.,Department of Anthropology, Macquarie University, Sydney, Australia.,School of Social Sciences, Monash University, Clayton, Australia.,Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia
| | - Chris Lyttleton
- Department of Anthropology, Macquarie University, Sydney, Australia
| | - Guy B Marks
- NHMRC Tuberculosis Centre of Research Excellence, Australia.,Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia.,University of New South Wales, Sydney, Australia
| | - Greg J Fox
- NHMRC Tuberculosis Centre of Research Excellence, Australia.,Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| |
Collapse
|
23
|
Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, Schumacher SG, Ochodo EA, Pai M, Steingart KR. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2019; 6:CD009593. [PMID: 31173647 PMCID: PMC6555588 DOI: 10.1002/14651858.cd009593.pub4] [Citation(s) in RCA: 115] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the newest version, are the only World Health Organization (WHO)-recommended rapid tests that simultaneously detect tuberculosis and rifampicin resistance in persons with signs and symptoms of tuberculosis, at lower health system levels. A previous Cochrane Review found Xpert MTB/RIF sensitive and specific for tuberculosis (Steingart 2014). Since the previous review, new studies have been published. We performed a review update for an upcoming WHO policy review. OBJECTIVES To determine diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for tuberculosis in adults with presumptive pulmonary tuberculosis (PTB) and for rifampicin resistance in adults with presumptive rifampicin-resistant tuberculosis. SEARCH METHODS We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature, Scopus, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number Registry, and ProQuest, to 11 October 2018, without language restriction. SELECTION CRITERIA Randomized trials, cross-sectional, and cohort studies using respiratory specimens that evaluated Xpert MTB/RIF, Xpert Ultra, or both against the reference standard, culture for tuberculosis and culture-based drug susceptibility testing or MTBDRplus for rifampicin resistance. DATA COLLECTION AND ANALYSIS Four review authors independently extracted data using a standardized form. When possible, we also extracted data by smear and HIV status. We assessed study quality using QUADAS-2 and performed meta-analyses to estimate pooled sensitivity and specificity separately for tuberculosis and rifampicin resistance. We investigated potential sources of heterogeneity. Most analyses used a bivariate random-effects model. For tuberculosis detection, we first estimated accuracy using all included studies and then only the subset of studies where participants were unselected, i.e. not selected based on prior microscopy testing. MAIN RESULTS We identified in total 95 studies (77 new studies since the previous review): 86 studies (42,091 participants) evaluated Xpert MTB/RIF for tuberculosis and 57 studies (8287 participants) for rifampicin resistance. One study compared Xpert MTB/RIF and Xpert Ultra on the same participant specimen.Tuberculosis detectionOf the total 86 studies, 45 took place in high tuberculosis burden and 50 in high TB/HIV burden countries. Most studies had low risk of bias.Xpert MTB/RIF pooled sensitivity and specificity (95% credible Interval (CrI)) were 85% (82% to 88%) and 98% (97% to 98%), (70 studies, 37,237 unselected participants; high-certainty evidence). We found similar accuracy when we included all studies.For a population of 1000 people where 100 have tuberculosis on culture, 103 would be Xpert MTB/RIF-positive and 18 (17%) would not have tuberculosis (false-positives); 897 would be Xpert MTB/RIF-negative and 15 (2%) would have tuberculosis (false-negatives).Xpert Ultra sensitivity (95% confidence interval (CI)) was 88% (85% to 91%) versus Xpert MTB/RIF 83% (79% to 86%); Xpert Ultra specificity was 96% (94% to 97%) versus Xpert MTB/RIF 98% (97% to 99%), (1 study, 1439 participants; moderate-certainty evidence).Xpert MTB/RIF pooled sensitivity was 98% (97% to 98%) in smear-positive and 67% (62% to 72%) in smear-negative, culture-positive participants, (45 studies). Xpert MTB/RIF pooled sensitivity was 88% (83% to 92%) in HIV-negative and 81% (75% to 86%) in HIV-positive participants; specificities were similar 98% (97% to 99%), (14 studies).Rifampicin resistance detectionXpert MTB/RIF pooled sensitivity and specificity (95% Crl) were 96% (94% to 97%) and 98% (98% to 99%), (48 studies, 8020 participants; high-certainty evidence).For a population of 1000 people where 100 have rifampicin-resistant tuberculosis, 114 would be positive for rifampicin-resistant tuberculosis and 18 (16%) would not have rifampicin resistance (false-positives); 886 would be would be negative for rifampicin-resistant tuberculosis and four (0.4%) would have rifampicin resistance (false-negatives).Xpert Ultra sensitivity (95% CI) was 95% (90% to 98%) versus Xpert MTB/RIF 95% (91% to 98%); Xpert Ultra specificity was 98% (97% to 99%) versus Xpert MTB/RIF 98% (96% to 99%), (1 study, 551 participants; moderate-certainty evidence). AUTHORS' CONCLUSIONS We found Xpert MTB/RIF to be sensitive and specific for diagnosing PTB and rifampicin resistance, consistent with findings reported previously. Xpert MTB/RIF was more sensitive for tuberculosis in smear-positive than smear-negative participants and HIV-negative than HIV-positive participants. Compared with Xpert MTB/RIF, Xpert Ultra had higher sensitivity and lower specificity for tuberculosis and similar sensitivity and specificity for rifampicin resistance (1 study). Xpert MTB/RIF and Xpert Ultra provide accurate results and can allow rapid initiation of treatment for multidrug-resistant tuberculosis.
Collapse
Affiliation(s)
- David J Horne
- University of WashingtonDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, and Firland Northwest TB CenterSeattleUSA
| | - Mikashmi Kohli
- McGill UniversityDepartment of Epidemiology, Biostatistics and Occupational HealthMontrealCanada
| | - Jerry S Zifodya
- University of WashingtonPulmonary and Critical Care Medicine325 9th Avenue – Campus Box 359762SeattleUSA98104
| | - Ian Schiller
- McGill University Health Centre ‐ Research InstituteDivision of Clinical EpidemiologyMontrealCanada
| | - Nandini Dendukuri
- McGill University Health Centre ‐ Research InstituteDivision of Clinical EpidemiologyMontrealCanada
| | | | | | - Eleanor A Ochodo
- Stellenbosch UniversityCentre for Evidence‐based Health Care, Faculty of Medicine and Health SciencesPO Box 241Cape TownSouth Africa8000
| | - Madhukar Pai
- McGill UniversityDepartment of Epidemiology, Biostatistics and Occupational HealthMontrealCanada
| | - Karen R Steingart
- Department of Clinical Sciences, Liverpool School of Tropical MedicineHonorary Research FellowPembroke PlaceLiverpoolUK
| |
Collapse
|
24
|
Schumacher SG, Denkinger CM. The impact of Xpert MTB/RIF—do we have a final answer? LANCET GLOBAL HEALTH 2019; 7:e161-e162. [DOI: 10.1016/s2214-109x(18)30493-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 10/22/2018] [Indexed: 10/27/2022]
|
25
|
DNA markers for tuberculosis diagnosis. Tuberculosis (Edinb) 2018; 113:139-152. [PMID: 30514496 DOI: 10.1016/j.tube.2018.09.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2018] [Revised: 09/23/2018] [Accepted: 09/27/2018] [Indexed: 02/07/2023]
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis complex (MTBC), is an infectious disease with more than 10.4 million cases and 1.7 million deaths reported worldwide in 2016. The classical methods for detection and differentiation of mycobacteria are: acid-fast microscopy (Ziehl-Neelsen staining), culture, and biochemical methods. However, the microbial phenotypic characterization is time-consuming and laborious. Thus, fast, easy, and sensitive nucleic acid amplification tests (NAATs) have been developed based on specific DNA markers, which are commercially available for TB diagnosis. Despite these developments, the disease remains uncontrollable. The identification and differentiation among MTBC members with the use of NAATs remains challenging due, among other factors, to the high degree of homology within the members and mutations, which hinders the identification of specific target sequences in the genome with potential impact in the diagnosis and treatment outcomes. In silico methods provide predictive identification of many new target genes/fragments/regions that can specifically be used to identify species/strains, which have not been fully explored. This review focused on DNA markers useful for MTBC detection, species identification and antibiotic resistance determination. The use of DNA targets with new technological approaches will help to develop NAATs applicable to all levels of the health system, mainly in low resource areas, which urgently need customized methods to their specific conditions.
Collapse
|
26
|
Uddin S, Khan FU, Ahmad T, Rehman MMU, Arif M. Two Years of Retrospective Study on the Incidence of Tuberculosis in Dir Lower Valley, Khyber Pakhtunkhwa, Pakistan. Hosp Pharm 2018; 53:344-349. [PMID: 30210154 PMCID: PMC6130118 DOI: 10.1177/0018578718758603] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background: Pakistan has high tuberculosis (TB) burden with alarming mortality and morbidity, and its rate increases day by day, especially in remote areas where access of quality health is not available. Objective: The objective of the study was to determine the incidence rate of pulmonary TB in the Dir valley among the suspected patients according to age-, gender-, and location-wise prevalence of the disease. Methods: A retrospective descriptive study was designed from January 2015 to December 2016. All the 556 people registered are suspected patients of pulmonary tuberculosis sputum smear (PTB-SS) positive, whereas the remaining cases were diagnosed with extra-pulmonary TB and hence excluded from the study. Results: The ratio of PTB-SS-positive cases was higher in females (50.5%, n = 281) compared with males (49.5%, n = 275). Furthermore, in the age group 1 to 20 years, the percentage of PTB-SS-positive cases was 28.1% (n = 156), in 21 to 40 years 40.3% (n = 224), in 41 to 60 years 18.7% (n = 104), in 61 to 80 years 11.2% (n = 62), and at age group >81 years, it was 1.8% (n = 10). No difference was found in the years 2015 and 2016 regarding PTB-SS-positive cases registration. Age and health care facilities (P < .000) and treatment outcome (P < .000) have a strong relationship. No significant relation was found with other demographics variables (P > 0.05). Conclusion: It was concluded from our finding that TB was considerably increased in the general population of District Dir (Lower), and proper supervision, diagnosis, treatment, and awareness of rapid prophylactic measures are needed to eradicate the issue.
Collapse
Affiliation(s)
| | | | - Tariq Ahmad
- Quaid-i-Azam University, Islamabad, Pakistan
| | | | | |
Collapse
|
27
|
C-reactive protein as a screening test for HIV-associated pulmonary tuberculosis prior to antiretroviral therapy in South Africa. AIDS 2018; 32:1811-1820. [PMID: 29847333 DOI: 10.1097/qad.0000000000001902] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND There is an urgent need for more accurate screening tests for tuberculosis(TB). We assessed the diagnostic accuracy of C-reactive protein (CRP) as a screening test for active TB in HIV-infected ambulatory adults. METHODS CRP levels were measured in blood collected at the time of HIV testing.Diagnostic accuracy of CRP for pulmonary TB was calculated (reference standard: TB culture), compared to the WHO 4-symptom screen, consisting of cough, fever, night sweats, and weight loss. Diagnostic accuracy was also calculated for CRP in a larger cohort of HIV-infected adults with a positive symptom screen (reference standard: clinical or microbiological TB). RESULTS Among 425 HIV-infected outpatients systematically tested for pulmonary TB, TB culture was positive in 42 (10%), 279 (66%) had at least one TB-related symptom and 197 (46%) had a CRP more than 5 mg/l. The sensitivity of CRP and the TB symptom screen to detect TB was the same [90.5%; 95% confidence interval 77.4-97.3] but specificity of CRP was higher than for the TB symptom screen (58.5% vs. 37.1%, P < 0.001). Of persons with no symptoms and normal CRP, 99 (98%) had no TB. In another cohort of 749 patients presenting with at least one TB-related symptom and clinically evaluated, CRP had a sensitivity of 98.7% and specificity of 48.3%. CONCLUSION In HIV-infected outpatients, CRP was as sensitive but substantially more specific than TB symptom screening. Use of CRP as a screening tool to exclude active TB could identify the same number of HIV-associated TB cases, but reduce the use of diagnostic sputum testing in TB-endemic regions.
Collapse
|
28
|
Pai M, Schumacher SG, Abimbola S. Surrogate endpoints in global health research: still searching for killer apps and silver bullets? BMJ Glob Health 2018; 3:e000755. [PMID: 29607104 PMCID: PMC5873542 DOI: 10.1136/bmjgh-2018-000755] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Accepted: 02/20/2018] [Indexed: 12/21/2022] Open
Affiliation(s)
- Madhukar Pai
- McGill Global Health Programs and McGill International TB Centre, McGill University, Montreal, Quebec, Canada
| | | | - Seye Abimbola
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.,School of Public Health, University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
29
|
Abstract
Global health security is increasingly reliant on vigilance to provide early warning of transnational health threats. In theory, this approach requires that sentinels, based in communities most affected by new or reemerging infectious diseases, deliver timely alerts of incipient risk. Medicalizing global safety also implies there are particular forms of insecurity that must be remedied to preempt disease spread. I examine vigilance in the context of spreading drug-resistant malaria in Southeast Asian border zones and argue that to act as sentinels, marginal groups vulnerable to infection must be able to articulate what social and behavioral factors prompt proliferating disease risks.
Collapse
Affiliation(s)
- Chris Lyttleton
- a Department of Anthropology , Macquarie University , Sydney , NSW , Australia
| |
Collapse
|
30
|
Haraka F, Nathavitharana RR, Schumacher SG, Kakolwa M, Denkinger CM, Gagneux S, Reither K, Ross A. Impact of diagnostic test Xpert MTB/RIF® on health outcomes for tuberculosis. THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2018. [DOI: 10.1002/14651858.cd012972] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Frederick Haraka
- Ifakara Health Institute; Bagamoyo Tanzania
- Swiss Tropical and Public Health Institute; Basel Switzerland
- University of Basel; Basel Switzerland
| | - Ruvandhi R Nathavitharana
- Beth Israel Deaconess Medical Center, Harvard Medical School; Division of Infectious Diseases; Boston USA
| | | | | | | | - Sebastien Gagneux
- Swiss Tropical and Public Health Institute; Basel Switzerland
- University of Basel; Basel Switzerland
| | - Klaus Reither
- Ifakara Health Institute; Bagamoyo Tanzania
- Swiss Tropical and Public Health Institute; Basel Switzerland
- University of Basel; Basel Switzerland
| | - Amanda Ross
- Swiss Tropical and Public Health Institute; Basel Switzerland
- University of Basel; Basel Switzerland
| |
Collapse
|
31
|
Lessells RJ, Cooke GS, McGrath N, Nicol MP, Newell ML, Godfrey-Faussett P. Impact of Point-of-Care Xpert MTB/RIF on Tuberculosis Treatment Initiation. A Cluster-randomized Trial. Am J Respir Crit Care Med 2017; 196:901-910. [PMID: 28727491 PMCID: PMC5649979 DOI: 10.1164/rccm.201702-0278oc] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Accepted: 07/20/2017] [Indexed: 02/01/2023] Open
Abstract
RATIONALE Point-of-care (POC) diagnostics have the potential to reduce pretreatment loss to follow-up and delays to initiation of appropriate tuberculosis (TB) treatment. OBJECTIVES To evaluate the effect of a POC diagnostic strategy on initiation of appropriate TB treatment. METHODS We conducted a cluster-randomized trial of adults with cough who were HIV positive and/or at high risk of drug-resistant TB. Two-week time blocks were randomized to two strategies: (1) Xpert MTB/RIF test (Cepheid, Sunnyvale, CA) performed at a district hospital laboratory or (2) POC Xpert MTB/RIF test performed at a primary health care clinic. All participants provided two sputum specimens: one for the Xpert test and the other for culture as a reference standard. The primary outcome was the proportion of participants with culture-positive pulmonary tuberculosis (PTB) initiated on appropriate TB treatment within 30 days. MEASUREMENTS AND MAIN RESULTS Between August 22, 2011, and March 1, 2013, 36 two-week blocks were randomized, and 1,297 individuals were enrolled (646 in the laboratory arm, 651 in the POC arm), 159 (12.4%) of whom had culture-positive PTB. The proportions of participants with culture-positive PTB initiated on appropriate TB treatment within 30 days were 76.5% in the laboratory arm and 79.5% in the POC arm (odds ratio, 1.13; 95% confidence interval, 0.51-2.53; P = 0.76; risk difference, 3.1%; 95% confidence interval, -16.2 to 10.1). The median time to initiation of appropriate treatment was 7 days (laboratory) versus 1 day (POC). CONCLUSIONS POC positioning of the Xpert test led to more rapid initiation of appropriate TB treatment. Achieving one-stop diagnosis and treatment for all people with TB will require simpler, more sensitive diagnostics and broader strengthening of health systems. Clinical trial registered with www.isrctn.com (ISRCTN 18642314) and www.sanctr.gov.za (DOH-27-0711-3568).
Collapse
Affiliation(s)
- Richard J. Lessells
- Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
- Africa Health Research Institute, KwaZulu-Natal, South Africa
| | - Graham S. Cooke
- Division of Infectious Diseases, Imperial College London, London, United Kingdom
| | - Nuala McGrath
- Africa Health Research Institute, School of Nursing and Public Health, University of KwaZulu-Natal, KwaZulu-Natal, South Africa
- Academic Unit of Primary Care and Population Sciences
- Department of Social Statistics and Demography, and
- Research Department of Epidemiology and Public Health, University College London, London, United Kingdom
| | - Mark P. Nicol
- Division of Medical Microbiology and
- Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; and
- National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa
| | - Marie-Louise Newell
- Global Health Research Institute, Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
| | - Peter Godfrey-Faussett
- Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
| |
Collapse
|
32
|
Abstract
Rapid and accurate diagnosis is critical for timely initiation of anti-tuberculosis (TB) treatment, but many people with TB (or TB symptoms) do not have access to adequate initial diagnosis. In many countries, TB diagnosis is still reliant on sputum microscopy, a test with known limitations. However, new diagnostics are starting to change the landscape. Stimulated, in part, by the success and rollout of Xpert MTB/RIF, an automated, molecular test, there is now considerable interest in new technologies. The landscape looks promising with a pipeline of new tools, particularly molecular diagnostics, and well over 50 companies actively engaged in product development, and many tests have been reviewed by WHO for policy endorsement. However, new diagnostics are yet to reach scale, and there needs to be greater convergence between diagnostics development and the development of shorter TB drug regimens. Another concern is the relative absence of non-sputum-based diagnostics in the pipeline for children, and of biomarker tests for triage, cure, and latent TB progression. Increased investments are necessary to support biomarker discovery, validation, and translation into clinical tools. While transformative tools are being developed, high-burden countries will need to improve the efficiency of their health care delivery systems, ensure better uptake of new technologies, and achieve greater linkages across the TB and HIV care continuum. While we wait for next-generation technologies, national TB programs must scale up the best diagnostics currently available, and use implementation science to get the maximum impact.
Collapse
|
33
|
Jones A, Pitts M, Al Dulayymi JR, Gibbons J, Ramsay A, Goletti D, Gwenin CD, Baird MS. New synthetic lipid antigens for rapid serological diagnosis of tuberculosis. PLoS One 2017; 12:e0181414. [PMID: 28806423 PMCID: PMC5555574 DOI: 10.1371/journal.pone.0181414] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Accepted: 07/01/2017] [Indexed: 01/30/2023] Open
Abstract
Background During pulmonary tuberculosis (PTB) antibodies are generated to trehalose esters of mycolic acids which are cell wall lipids of Mycobacterium tuberculosis (Mtb). Attempts have been made to use these complex natural mixtures in serological tests for PTB diagnosis. Aim The aim of this work was to determine whether a serological test based on a panel of defined individual trehalose esters of characteristic synthetic mycolic acids has improved diagnostic accuracy in distinguishing patients with culture positive PTB from individuals who were Mtb culture negative. Method One hundred serum samples from well-characterized patients with presumptive tuberculosis, and diagnosed as having pulmonary smear and culture positive TB, or being culture and smear negative were evaluated by ELISA using different combinations of synthetic antigens and secondary antibodies. Using cut-off values determined from these samples, we validated this study blind in samples from a further 249 presumptive TB patients. Results With the first 100 samples, detailed responses depended both on the precise structure of the antigen and on the secondary antibody. Using a single antigen, a sensitivity/specificity combination for smear and culture positive PTB detection of 85 and 88% respectively was achieved; this increased to 96% and 95% respectively by a statistical combination of the results with seven antigens. In the blind study a sensitivity/specificity of 87% and 83% was reached with a single antigen. With some synthetic antigens, the responses from all 349 samples were significantly better than those with the natural mixture. Combining the results for seven antigens allowed a distinction between culture positive and negative with a ROC AUC of 0.95. Conclusion We have identified promising antigen candidates for serological assays that could be used to diagnose PTB and which could be the basis of a much-needed, simple, rapid diagnostic test that would bring care closer to communities.
Collapse
Affiliation(s)
- Alison Jones
- School of Chemistry, Bangor University, Bangor, Gwynedd, Wales, United Kingdom
| | - Mark Pitts
- School of Chemistry, Bangor University, Bangor, Gwynedd, Wales, United Kingdom
| | | | - James Gibbons
- School of Environment, Natural Resources and Geography, Bangor University, Bangor, Gwynedd, Wales, United Kingdom
| | - Andrew Ramsay
- Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organisation, Geneva, Switzerland
- University of St Andrews Medical School, St. Andrews, Scotland, United Kingdom
| | - Delia Goletti
- Translational Research Unit, Department of Epidemiology and Preclinical Research, ‘L. Spallanzani’ National Institute for Infectious Diseases, Rome, Italy
| | | | - Mark S. Baird
- School of Chemistry, Bangor University, Bangor, Gwynedd, Wales, United Kingdom
- * E-mail:
| |
Collapse
|
34
|
Méndez-Samperio P. Diagnosis of Tuberculosis in HIV Co-infected Individuals: Current Status, Challenges and Opportunities for the Future. Scand J Immunol 2017; 86:76-82. [PMID: 28513865 DOI: 10.1111/sji.12567] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Accepted: 05/07/2017] [Indexed: 02/03/2023]
Abstract
Tuberculosis (TB) remains one of the most important causes of death among people co-infected with human immunodeficiency virus (HIV). The diagnosis of TB remains challenging in HIV co-infected individuals, due to a high frequency of smear-negative disease and high rates of extrapulmonary TB. Accurate, ease of use and rapid diagnosis of active TB are critical to the World Health Organization (WHO) End TB Strategy by 2050. Traditional laboratory techniques do not provide rapid and accurate results to effectively manage HIV co-infected patients. Over the last decade, molecular methods have provided significant steps in the fight against TB. However, many HIV co-infected patients do not have access to these molecular diagnostic tests. Given the costs closely related with confirming a TB diagnosis in HIV patients, an overtreatment for TB is used in this patient population. Nowadays, an estimated US $8 billion a year is required to provide TB treatment, which is very high compared with making an important strategy to improve the current diagnostic tests. This review focuses on current advances in diagnosing active TB with an emphasis on the diagnosis of HIV-associated TB. Also discussed are the main challenges that need to be overcome for improving an adequate initial diagnosis of active TB in HIV-positive patients.
Collapse
Affiliation(s)
- P Méndez-Samperio
- Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, IPN, México, México
| |
Collapse
|
35
|
Hermans SM, Babirye JA, Mbabazi O, Kakooza F, Colebunders R, Castelnuovo B, Sekaggya-Wiltshire C, Parkes-Ratanshi R, Manabe YC. Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study. BMC Infect Dis 2017; 17:433. [PMID: 28622763 PMCID: PMC5473987 DOI: 10.1186/s12879-017-2534-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Accepted: 06/07/2017] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND The Xpert™ MTB/RIF (XP) has a higher sensitivity than sputum smear microscopy (70% versus 35%) for TB diagnosis and has been endorsed by the WHO for TB high burden countries to increase case finding among HIV co-infected presumptive TB patients. Its impact on the diagnosis of smear-negative TB in a routine care setting is unclear. We determined the change in diagnosis, treatment and mortality of smear-negative presumptive TB with routine use of Xpert MTB/RIF (XP). METHODS Prospective cohort study of HIV-positive smear-negative presumptive TB patients during a 12-month period after XP implementation in a well-staffed and trained integrated TB/HIV clinic in Kampala, Uganda. Prior to testing clinicians were asked to decide whether they would treat empirically prior to Xpert result; actual treatment was decided upon receipt of the XP result. We compared empirical and XP-informed treatment decisions and all-cause mortality in the first year. RESULTS Of 411 smear-negative presumptive TB patients, 175 (43%) received an XP; their baseline characteristics did not differ. XP positivity was similar in patients with a pre-XP empirical diagnosis and those without (9/29 [17%] versus 14/142 [10%], P = 0.23). Despite XP testing high levels of empirical treatment prevailed (18%), although XP results did change who ultimately was treated for TB. When adjusted for CD4 count, empirical treatment was not associated with higher mortality compared to no or microbiologically confirmed treatment. CONCLUSIONS XP usage was lower than expected. The lower sensitivity of XP in smear-negative HIV-positive patients led experienced clinicians to use XP as a "rule-in" rather than "rule-out" test, with the majority of patients still treated empirically.
Collapse
Affiliation(s)
- Sabine M Hermans
- Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda.
- Department of Internal Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
- Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
| | - Juliet A Babirye
- Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda
| | - Olive Mbabazi
- Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda
| | - Francis Kakooza
- Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda
| | - Robert Colebunders
- Institute for Tropical Medicine, University of Antwerp, Antwerp, Belgium
- Global Health Institute, University of Antwerp, Antwerp, Belgium
| | - Barbara Castelnuovo
- Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda
| | | | - Rosalind Parkes-Ratanshi
- Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda
- Institute of Public Health, University of Cambridge, Cambridge, UK
| | - Yukari C Manabe
- Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda
- Department of Internal Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
- Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
| |
Collapse
|
36
|
Scott L, da Silva P, Boehme CC, Stevens W, Gilpin CM. Diagnosis of opportunistic infections: HIV co-infections - tuberculosis. Curr Opin HIV AIDS 2017; 12:129-138. [PMID: 28059955 PMCID: PMC6024079 DOI: 10.1097/coh.0000000000000345] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW Tuberculosis (TB) incidence has declined ∼1.5% annually since 2000, but continued to affect 10.4 million individuals in 2015, with 1/3 remaining undiagnosed or underreported. The diagnosis of TB among those co-infected with HIV is challenging as TB remains the leading cause of death in such individuals. Accurate and rapid diagnosis of active TB will avert mortality in both adults and children, reduce transmission, and assist in timeous decisions for antiretroviral therapy initiation. This review describes advances in diagnosing TB, especially among HIV co-infected individuals, highlights national program's uptake, and impact on patient care. RECENT FINDINGS The TB diagnostic landscape has been transformed over the last 5 years. Molecular diagnostics such as Xpert MTB/RIF, which simultaneously detects Mycobacterium tuberculosis (MTB) resistance to rifampicin, has revolutionized TB control programs. WHO endorsed the use of Xpert MTB/RIF in 2010 for use in HIV/TB co-infected patients, and later in 2013 for use as the initial diagnostic test for all adults and children with signs and symptoms of pulmonary TB. Line probe assays (LPAs) are recommended for the detection of rifampicin and isoniazid resistance in sputum smear-positive specimens and mycobacterial cultures. A second-line line probe assay has been recommended for the diagnosis of extensively drug-resistant (XDR)-TB Assays such as the urine lateral flow (LF)-lipoarabinomannan (LAM), can be used at the point of care (POC) and have a niche role to supplement the diagnosis of TB in seriously ill HIV-infected, hospitalized patients with low CD4 cell counts of less than 100 cells/μl. Polyvalent platforms such as the m2000 (Abbott Molecular) and GeneXpert (Cepheid) offer potential for integration of HIV and TB testing services. While the Research and Development (R&D) pipeline appears to be rich at first glance, there are actually few leads for true POC tests that would allow for earlier TB diagnosis or rapid, comprehensive drug susceptibility testing, especially when considering the very high attrition rates observed between biomarker discovery and product market entry. SUMMARY In this review, we describe diagnostic strategies specifically for HIV and TB co-infected individuals. Molecular diagnostics in particular within the past 5 years have revolutionized and 'disrupted' this field. They lend themselves to integration of services with platforms capable of polyvalent testing. Impact on patient care is, however, still debatable. What has been highlighted is the need for health system strengthening and for true POC testing that can be used in active case finding.
Collapse
Affiliation(s)
- Lesley Scott
- aDepartment of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa bNational Priority Programs, National Health Laboratory Service, Johannesburg, Gauteng, South Africa cFoundation for Innovative New Diagnostics, Geneva dGlobal TB Program, WHO, Geneva, Switzerland
| | | | | | | | | |
Collapse
|
37
|
Wang G, Yang X, Zhu J, Dong W, Huang M, Jiang G, Zhao L, Qin S, Chen X, Huang H. Evaluation of the efficacy of Myco/F lytic system, MGIT960 system and Lowenstein-Jensen medium for recovery of Mycobacterium tuberculosis from sterile body fluids. Sci Rep 2016; 6:37757. [PMID: 27876877 PMCID: PMC5120269 DOI: 10.1038/srep37757] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Accepted: 10/31/2016] [Indexed: 01/15/2023] Open
Abstract
The diagnosis of extrapulmonary tuberculosis (EPTB) is challenging due to non-specific symptoms, invasive approach for specimen collection and most importantly, the paucibacillary status. The objective of this assay was to evaluate the efficacy of Myco/F lytic system, BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 system and Lowenstein-Jensen (L-J) medium for recovery of bacilli from sterile body fluids. 214 specimens (114 pleural fluid and 100 pus) from clinically diagnosed EPTB patients were collected and subjected to Ziehl-Neelsen (ZN) smear microscopy, L-J culture, MGIT 960 culture and Myco/F lytic culture.103 out of the 214 sterile body fluid samples yielded positive culture outcomes by any of the three methods. Among all the culture positive specimens, the recovery rate was 86.41% for Myco/F lytic, 75.73% for MGIT 960, and 42.72% for L-J medium. The mean time to positivity (TTP) was 27.06 ± 8.03 days for Myco/F lytic, 22.20 ± 7.84 days for MGIT960 and 42 ± 8.84 days for L-J medium. The rates of contamination were 6.54%, 3.74% and 2.80% for Myco/F lytic, MGIT960 and L-J medium respectively. Both Myco/F lytic and MGIT960 system were superior to L-J medium for recovery of bacilli from sterile body fluids. Myco/F lytic system was more favorable than MGIT960 regarding recovery rate and cost-effectiveness, thus can be considered as a promising alternative to MGIT960 system for diagnosing EPTB.
Collapse
Affiliation(s)
- Guirong Wang
- National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
| | - Xinting Yang
- Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
| | - Junping Zhu
- Department of Pathogenic Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China
| | - Weijie Dong
- Department of Orthopedics, Beijing Bone and Joint Tuberculosis Diagnosis and Treatment Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
| | - Mailing Huang
- Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
| | - Guanglu Jiang
- National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
| | - Liping Zhao
- National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
| | - Sibing Qin
- Department of Orthopedics, Beijing Bone and Joint Tuberculosis Diagnosis and Treatment Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
| | - Xiaoyou Chen
- Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
| | - Hairong Huang
- National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
| |
Collapse
|